Aurobindo Pharma

Complex Generics And Biosimilars Will Fuel Secular Demand

AnalystHighTarget

Not Invested

Community Contributor

Published

20 Jun 25

AnalystHighTarget's Fair Value

₹1,723.98

35.8% undervalued

10 Sep

₹1,106.30

-24.7%

-1.2%

-24.7%

-1.2%

You can edit this narrative until Jun 20 9:11 PM. Then, changes will post as Updates.

Author's Valuation

₹1.72k35.8% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

₹1.72k

35.8% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

7.83%

Pharma revenue growth rate

0.68%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

12.73%

Calculation

₹57.38b

Earnings '28

24.57x

PE Ratio '28

₹1.41t

Market Cap '28

₹1.41t

Market Cap '28

571.80m

No. shares '28

₹2.47k

Share Price '28

₹2.47k Share Price '28

Discounted to 2025 @ 12.73% p.a.

₹1.72k

Fair Value '25